Evofem Biosciences, Inc. (EVFM) Analysts See $-0.41 EPS on May, 10

May 3, 2018 - By Ira Colvard

On May, 10 WallStreet expected Evofem Biosciences, Inc. (NASDAQ:EVFM)’s earnings report, as reported by Faxor. The EPS diference is $0.91 or 68.94 % up from last years number. Previous year: $-1.32; Analysts forcast: $-0.41. EVFM reached $6.95 during the last trading session after $0.49 change.Evofem Biosciences, Inc. has 16,143 shares volume, 31.18% up from normal. EVFM is and has moved 0.00% since May 3, 2017. The stock underperformed the S&P500 by 11.55%.

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women.The firm is valued at $123.46 million. The company's product includes, Amphora contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections, and antimicrobial drug product to prevent the reoccurrence of bacterial vaginosis.Last it reported negative earnings. It also offers AMPOWER clinical research study, Chlamydia/Gonorrhea prevention clinical trial, and reduction in the recurrence of bacterial vaginosis clinical trial.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.